When living with metastatic non-small cell lung cancer (NSCLC)...
CYRAMZA can help keep you fighting for what matters to you
You’re not the type to settle for average. You’re the type who pushes for more. But where individual results with CYRAMZA can vary, clinical studies have shown…
More time without disease progression
36% of people had delayed disease progression for 6 months or longer with CYRAMZA + docetaxeI (a type of chemotherapy) vs 29% with chemotherapy alone
- Half of the people who received CYRAMZA + chemotherapy lived without their cancer getting worse for 4.5 months vs 3.0 months with chemotherapy alone
More people had tumor shrinkage
More people had their tumors shrink with CYRAMZA + chemotherapy vs chemotherapy alone
- Tumors shrank (by 30% or more) in 23% of people taking CYRAMZA + chemotherapy vs 14% taking chemotherapy alone
Cyramza may help you live longer
43% of people lived 1 year or longer with CYRAMZA + chemotherapy vs 38% with chemotherapy alone
- Half of the people who received CYRAMZA + chemotherapy after their cancer progressed were still alive at 10.5 months vs 9.1 months with chemotherapy alone
CYRAMZA was studied in a clinical trial of 1253 people with metastatic non-small cell lung cancer who received CYRAMZA + docetaxel (628 people) vs those who received docetaxel alone (625 people). All people in the study had previously received platinum-containing chemotherapy.